Physician profile
Scott Daniel Forester
NPI 1861578080
$16,563.10
in general payments reported to CMS, 2019-2025
23 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,884 · 2020: $1,724 · 2021: $3,026 · 2022: $3,005 · 2023: $1,765 · 2024: $2,054 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,923.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,643.69 | 2019-2025 | Total30, Precision7, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $5,868.99 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $975.70 | 2022-2025 | Infuse, Biotrue One Day, Miebo |
| Glaukos Corporation | $671.51 | 2019-2024 | Idose |
| Coopervision INC. | $506.44 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $363.49 | 2019-2021 | |
| Abbvie INC. | $356.35 | 2022-2025 | |
| Oyster Point Pharma, INC. | $168.12 | 2022-2024 | Tyrvaya |
| Abb Con-Cise Optical Group LLC | $148.12 | 2019-2025 | Contact Lens |
| Maculogix, INC. | $120.20 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $114.09 | 2024-2025 | Xdemvy |
| Allergan, INC. | $113.09 | 2019-2021 | |
| Dompe US, INC. | $108.35 | 2024-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $79.01 | 2019-2021 | |
| Harrow Eye, LLC | $71.56 | 2024-2025 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $65.60 | 2019 | |
| Sight Sciences, INC. | $43.83 | 2021 | |
| Kala Pharmaceuticals, INC. | $31.98 | 2022 | |
| Sun Pharmaceutical Industries INC. | $26.93 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $24.14 | 2020-2021 | |
| Astellas Pharma US INC | $23.46 | 2025 | Izervay |
| Spark Therapeutics, INC. | $21.30 | 2022 | |
| Optos, INC. | $17.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Forester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.